熱門資訊> 正文

Teva获得安进Xgeva的生物仿制药批准

2026-09-29 04:57

The US FDA approved Teva Pharmaceutical Industries' (TEVA) Degvema (denosumab-adet), a biosimilar to Amgen's (AMGN) Xgeva (denosumab), which is indicated to prevent bone damage and complications in cancer patients.
Approval was based on analytical and clinical data showing Degvema has similar efficacy, safety, and immunogenicity profile as Xgeva.
Teva was granted approval for Ponlimsi, a denosumab biosimilar to Amgen's osteoporosis treatment Prolia, in March.
Amgen reported worldwide revenue for Xgeva of $763M in H1 2026.

More on Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited (TEVA) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Teva Pharmaceutical Industries Limited (TEVA) Presents at U.S. All Stars Conference Transcript
Teva Pharmaceutical Industries Limited (TEVA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Trump seeks to produce more generic drugs in the US
Viatris, Teva initiated at Outperform at Oppenheimer

推薦文章

風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。